See how AbbVie Inc. and Visa Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Visa Inc. is the world’s largest payment processor. In fiscal 2025, the company handled nearly $17 trillion in total payment volume. Visa operates in more than 200 countries and territories and processes transactions in over 160 currencies. Its network is capable of handling more than 65,000 transactions per second.